Primary gliosarcoma: epidemiology, clinical presentation, management and survival.
Gliosarcomas are malignant tumours of the central nervous system. As glioblastomas (GBM), they are treated in a similar fashion. However there is growing evidence to suggest that they may be a separate entity. Due to the rarity of primary gliosarcomas (PGS)Here we publish single centre data over a 14-year period, comprising possibly one of the biggest case series in the literature to our knowledge. The mean age at presentation was 59 years with male preponderance (1.75:1). The most common presenting symptoms were balance and mobility issues (61%), followed by headaches (50%) and visual problems (39%). Tumours were most likely to involve the frontal and parietal lobes (27% and 21% respectively). Patients under 50 had a significant survival advantage (50% versus 32%). All patients had surgery, 79% had adjuvant radiotherapy, with a further 21% also receiving chemotherapy. Median survival from surgery of patients diagnosed with PGS was 6.6 months. Median and one-year survival were significantly better for patients who received radiotherapy (14 months; 46% one year survival) and improved further with combined radioand chemotherapy (30 months; 77%, one year survival). For patients of good status, adjuvant chemo-radiotherapy is warranted and should be offered as it confers a muchimproved overall survival.